Fruquintinib - HUTCHMED
Alternative Names: Aiyoute; Elunate; FRUZAQLA; HMPL-013; TAK-113Latest Information Update: 02 May 2024
At a glance
- Originator Hutchison MediPharma
- Developer BeiGene; Eli Lilly and Company; Genor Biopharma; Hutchison MediPharma; HUTCHMED; Shanghai Junshi Biosciences
- Class Antineoplastics; Benzofurans; Quinazolines; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer
- Preregistration Endometrial cancer; Gastric cancer
- Phase III Non-small cell lung cancer
- Phase II/III Renal cell carcinoma
- Phase II Solid tumours
- Phase I/II Triple negative breast cancer
Most Recent Events
- 26 Apr 2024 CHMP recommends approval of Fruquintinib for Colorectal cancer (In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in European Union
- 26 Apr 2024 Adverse events data from the phase-III FRESCO-2 trial in Colorectal cancer released by Takeda
- 02 Apr 2024 Preregistration for Endometrial cancer (Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease, Late-stage disease, Combination therapy) in China (PO), prior to April 2023 (NCT03903705)